循环核酸化酶1和认知障碍:机制性见解和治疗影响
Hailiang Li1, Olivia Brzostek1, Jason Sherman1
1Department of Anesthesiology, Rutgers University, The State University of New Jersey, Newark, NJ 07103, United States.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|November 22, 2025
概括
循环核酸化酶1 (PDE1) 通过调节循环核酸水平,在认知功能中起着关键作用. 抑制PDE1A在治疗像阿尔茨海默氏症这样的神经退行性疾病中的记忆缺陷方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 认知障碍是神经退行性疾病的标志,如阿尔茨海默病 (AD) 和血管痴呆症 (VaD).
- 正确的驱动认知衰退的机制涉及复杂的病理过程和多个信号通路.
- 循环核酸化酶1 (PDE1) 调节细胞内cAMP和cGMP,这是神经元功能中的关键第二信使.
研究的目的:
- 审查中枢神经系统 (CNS) 中PDE1异型 (PDE1A,PDE1B,PDE1C) 的分布,调节和功能.
- 探索PDE1在调节cAMP/PKA和cGMP/PKG信号通路中的作用,这与认知功能障碍相关.
- 突出PDE1在认知障碍中的双重神经血管作用,并总结治疗策略.
主要方法:
- 文献综述总结了关于中枢神经系统疾病中PDE1的现有研究.
- 对PDE1参与氧化应激,神经炎症和亡的分析.
- 检查PDE1对神经元和血管调节认知的影响.
主要成果:
- PDE1将信号与循环核酸代谢结合在一起,影响突触可塑性,神经元生存和神经炎症.
- PDE1异型因氧化压力,神经炎症和亡级联而导致认知衰退.
- 在AD和VaD模型中,PDE1A抑制剂在缓解记忆缺陷方面表现出有效性.
结论:
- 通过调节关键信号通路,PDE1在认知功能中起着至关重要的作用.
- 针对PDE1,特别是PDE1A,为表现为认知障碍的神经退行性疾病提供了一个有前途的治疗途径.
- 对PDE1的神经血管作用的进一步研究对于开发有效的认知功能障碍治疗方法至关重要.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
523
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
523
Protein Kinases and Phosphatases
14.9K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
14.9K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
Long-term Potentiation
3.4K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
3.4K
Long-term Potentiation
58.2K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
58.2K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


